Renal Osteodystrophy News and Research

RSS

What bone and cardiovascular consequences are associated with aluminum intoxication and accumulation?

Researchers aimed to detect the diagnosis of bone aluminum (Al) accumulation and its consequences on bone and heart health.

21 Apr 2023

New concise recommendations for managing osteoporosis in patients with chronic kidney disease

Patients with advanced chronic kidney disease (CKD) typically suffer from impaired bone quality and quantity, with a non-vertebral fracture risk which is 4-to 6-fold higher than the fracture risk of matched controls. However, despite their high risk of fragility fractures, the vast majority of patients with chronic CKD stages 4 to 5D, are not receiving osteoporosis therapy.

15 Jul 2021

Experts publish Consensus Statement on management of osteoporosis in patients with CKD G4–G5D

Patients with advanced chronic kidney disease (CKD) suffer from impaired bone quality and quantity, with a non-vertebral fracture risk which is 4-to 6-fold higher than the fracture risk of matched controls.

11 Nov 2020

Kanis receives Hamdan Award for Medical Research Excellence in osteoporosis

Professor John A. Kanis is the winner of the 2010 Hamdan Award for Medical Research Excellence in the field of osteoporosis. The prestigious Award honours his outstanding contribution to the development and validation of a widely used fracture risk assessment tool

21 Dec 2010

Major bone-related meetings to take place in Valencia, Spain in March 2011

Two bone-related meetings, jointly organized by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis and International Osteoporosis Foundation will take place in Valencia, Spain in March 2011.

11 Aug 2010

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced a collaboration and license agreement with Panacor Bioscience Ltd. to develop and commercialize its Nephoxil(R) pharmaceutical product for the treatment of hyperphosphatemia in China.

8 Feb 2010

Acologix demonstrates improved bone architecture in rat model of chronic kidney disease

Acologix, Inc. will present data indicating that its therapeutic product candidate AC-200 improved bone architecture in a rat model of chronic kidney disease.

8 Nov 2008

Approval for FOSRENOL (lanthanum carbonate), which controls phosphate levels in renal dialysis patients

Sweden's MPA has today granted the first regulatory approval in the world for FOSRENOL (lanthanum carbonate), a non-calcium, non-aluminium phosphate binding medicine developed to control phosphate levels in renal dialysis patients. Sweden will now become the Reference Member State in the EU Mutual Recognition Procedure for FOSRENOL, and this is the first step in securing marketing approval throughout Europe. A submission has also been made by Shire to gain marketing approval for FOSRENOL in the United States.

25 Mar 2004

Renal Osteodystrophy News and Research

What bone and cardiovascular consequences are associated with aluminum intoxication and accumulation?

New concise recommendations for managing osteoporosis in patients with chronic kidney disease

Experts publish Consensus Statement on management of osteoporosis in patients with CKD G4–G5D

Kanis receives Hamdan Award for Medical Research Excellence in osteoporosis

Major bone-related meetings to take place in Valencia, Spain in March 2011

3SBio announces Nephoxil collaboration and license agreement with Panacor Bioscience

Acologix demonstrates improved bone architecture in rat model of chronic kidney disease

Approval for FOSRENOL (lanthanum carbonate), which controls phosphate levels in renal dialysis patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News